[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558035":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":19,"responsibleParty":33,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":7,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Ferring Pharmaceuticals","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Global Clinical Compliance","STUDY_DIRECTOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+1 833-548-1402 (US\u002FCanada)","DK0-Disclosure@ferring.com",{"name":10,"role":14,"phone":18,"phoneExt":7,"email":16},"+1 862-286-5200 (outside US)",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":7},"Ferring Investigational Site","RECRUITING","Omitama","Ibaraki","Japan","JP",{"type":28,"coordinates":29},"Point",[30,31],140.37962,36.25449,{"lat":31,"lon":30},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100558035","rekovelle-pen-for-sc-injection-general-drug-use-survey-controlled-ovarian-stimulation-in-assisted-reproductive-technologies-100558035",false,"NCT06545877","REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)","REKOVELLE® PEN S.C. Injection 12μg\u002F36μg\u002F72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey","Inclusion Criteria:\n\n* Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.\n\nExclusion Criteria:\n\n* No exclusion criteria because data are collected under conditions of use in daily practice.","FEMALE",{"count":44,"type":45},500,"ESTIMATED","OBSERVATIONAL","This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).",[49],"Infertility","2025-08-14",{"date":52,"type":53},"2025-08-20","ACTUAL",{"date":55,"type":53},"2022-09-16",{"date":57,"type":45},"2029-06-22",{"name":5,"class":6},1]